NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant

Adaptive Trial Skips Monotherapy Arm, Uses Factorial Design

Eli Lilly’s drug is one of many anti-inflammatory medicines in late-stage trials against coronavirus but will be the first to be combined with Gilead’s recently approved remdesivir.

BETHESDA, MD - JUNE 29, 2019: NIH NATIONAL INSTITUTES OF HEALTH sign emblem seal on gateway center entrance building at NIH campus
The NIH's NIAID is leading an international consortium in the second ACTT study

The US National Institutes of Health (NIH) is to build on its ground-breaking ACTT trial of Gilead Sciences Inc.’s remdesivir in COVID-19 patients by adding Eli Lilly & Co.’s rheumatoid arthritis drug Olumiant (baricitinib) into the mix for patients with more severe disease.

The initial ACTT data formed the basis of the US Food and Drug Administration’s emergency use approval of remdesivir on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip